GlaxoSmithKline CEO Sir Andrew Witty may have been pressured out for not building shareholder value fast enough. But some experts think he has built the kind…

Good news for Valeant investors worried about the drugmaker defaulting on its mountain of debt: Its creditors are giving it some breathing room.

With the former Novartis flu vaccine unit in hand, CSL has big plans for its newly formed flu vaccines unit Seqirus. But it’ll be a bumpy path toward reaching…

A large portion of drugs under the “orphan” umbrella are used on-label and off-label to treat more common maladies, and those uses have been associated with…

Medivation posted second-quarter numbers on Tuesday, and they offer more evidence why Big Pharma and Big Biotech are stumbling over themselves to snap up the…

BMS' Opdivo failed its lung cancer trial a few days ago now, but the pharma world is still digesting the news--and new sales estimates, ripple-effect…

Valeant is working on a three-point plan to stabilize, turn around and transform its business. But how much progress it made on that front in Q2 has been…

GlaxoSmithKline has struck a money-back guarantee on its gene therapy Strimvelis. The once-and-done treatment for “bubble boy” disease, only the second of its…